Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 9/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8509721 | 1.00 | GRM2 (0.38) | GRM2SCN9AJAK2JAK1TYK2 | |
| SCHEMBL8511930 | 0.91 | SCN9A (0.42) | GRM2SCN9AGPR119FPR2BACE1 | |
| SCHEMBL8509769 | 0.89 | GRM2 (0.41) | GRM2JAK2JAK1TYK2GPR119 | |
| SCHEMBL9604231 | 0.88 | GRM2 (0.39) | GRM2JAK2JAK1TYK2FPR2 | |
| SCHEMBL8513148 | 0.88 | GRM2 (0.39) | GRM2JAK2JAK1TYK2FPR2 | |
| SCHEMBL9604240 | 0.88 | GRM2 (0.39) | GRM2JAK2JAK1TYK2FPR2 | |
| SCHEMBL8513458 | 0.88 | GRM2 (0.41) | GRM2 | |
| SCHEMBL8509456 | 0.88 | GRM2 (0.41) | GRM2SCN9A | |
| SCHEMBL8511770 | 0.87 | SCN9A (0.49) | GRM2SCN9AFPR2BACE1 | |
| SCHEMBL9604238 | 0.86 | GRM2 (0.38) | GRM2JAK2JAK1TYK2FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785481-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785481-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120135977-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
| US-20120135977-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135977-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | GRM2, GRIA2, GRIK2 | GRM2 1/4885SCN9A 3983/4885JAK2 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.